IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
IRADIMED (NASDAQ: IRMD) will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IRADIMED (NASDAQ: IRMD) will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026.
Company management will host a conference call the same day at 11:00 a.m. Eastern Time, available by registration for dial-in details and via a real-time webcast. A recording will be posted on the investor website after the call.
Details
News Market Reaction – IRMD
On Feb 5, the first trading day after this news, IRMD closed 0.74% above the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Q3 2025 revenue
- $21.2M
- Record Q3 2025 financial results
- Q3 2025 GAAP EPS
- $0.43
- Record GAAP diluted EPS in Q3 2025
- Q3 2025 non-GAAP EPS
- $0.47
- Non-GAAP diluted EPS, +9% YoY in Q3 2025
- 2025 revenue guidance
- $82.5M–$83.5M
- Raised full-year 2025 revenue guidance
- 2025 GAAP EPS guidance
- $1.68–$1.72
- Raised full-year 2025 GAAP EPS guidance
- Q3 2025 gross margin
- 78%
- Gross margin level in record Q3 2025
- Special dividend
- $0.50 per share
- Special cash dividend payable Dec 30, 2025
- Cash balance
- $56.5M
- Cash and cash equivalents at end of Q3 2025
Previous Conferences,earnings Reports
-
Scheduled Q3 2025 results release and conference call with registration details.
-
Announced Q2 2025 results timing and 11:00 a.m. Eastern conference call.
-
Outlined corrected Q1 2025 results date and 9:00 a.m. call schedule.
-
Initial Q1 2025 results and conference call timing with registration link.
-
Set Q4 and full-year 2024 results release and 11:00 a.m. conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI9eabdb5f5ea54652b0bd15ed7530706e. Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.